Search results
Results from the WOW.Com Content Network
Previously, on 30 June 2020, the NHS changed its website, replacing the statement that puberty blockers were "fully reversible" and that "treatment can usually be stopped at any time"; with "little is known about the long-term side effects of hormone or puberty blockers in children with gender dysphoria.
The Cass Review into children’s gender services has prompted a change in approach.
While the recent decision by the NHS cites a lack of research surrounding the long-term effects of puberty blockers, the treatment has been a medically accepted practice since the late 1980s ...
On 18 April 2024, NHS Scotland announced that it had paused prescribing puberty blockers to children referred by its specialist gender clinic. [249] The chief medical officer of Scotland set up a multidisciplinary clinical team to assess how the Cass Review's 32 recommendations might be applied to NHS Scotland .
Puberty blockers are licensed to treat early-onset puberty in children – but over the past decade, there has been a significant increase in demand for them to be given to children and young ...
Researchers have recommended puberty blockers after age 12, when the person has developed to Tanner stages 2–3, and then cross-sex hormones treatment at age 16. This use of the drug is off-label, however, not having been approved by the Food and Drug Administration and without data on long-term effects of this use. [needs update] [18]
Neyman and colleagues in 2019 published a study on bicalutamide as a puberty blocker in adolescent transgender girls. [ 95 ] [ 101 ] : 477 It was employed both alone (n=17) and in combination with estrogen (n=6) at a dose of 50 mg/day in 23 transgender girls (mean age of 16 years, range 12 to 18.4 years) between 2013 and 2018.
England’s National Health Service will stop prescribing puberty blockers to kids with gender dysphoria or incongruence. Here’s what to know about the medicine. What to know about puberty blockers